Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Acorda Therapeutics will reduce its staff by 20%, or about 120 jobs, after a decision by a U.S. district court to invalidate patents related to one of its main products, the multiple sclerosis treatment Ampyra. Acorda says it will focus on its two late-stage developmental drugs for Parkinson’s disease, CVT-301 and tozadenant. Meanwhile, Aviragen Therapeutics will reduce its staff by 25%, or about six employees, after clinical trial setbacks for two drugs. Aviragen says it will explore a sale or merger of the company.
This article has been sent to the following recipient: